Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2024 Q3 | Sep 30, 2024 | ITUS Capital | - | - | ABB.NS, AUROPHARMA.NS, BAJAJ-AUTO.NS, BHARATFORG.NS, BLUESTARCO.NS, DRREDDY.NS, EICHERMOT.NS, GAIL.NS, HAVELLS.NS, ICICIGI.NS, IEX.NS, IPCALAB.NS, ITC.NS, MARICO.NS, MARUTI.NS, NTPC.NS, PETRONET.NS, POWERGRID.NS, RELIANCE.NS, SBILIFE.NS | Autos, earnings, India, large cap, liquidity, Pharmaceuticals, Power, Rural | Strong earnings growth driven by domestic fundamentals with portfolio companies showing 30.6% EPS growth year-over-year. Structural improvement in RoEs for top 500 companies in India over the last 4 years has resulted in strong market performance. Focus on companies where earnings growth is accompanied by RoE expansion. | View | |
| 2025 Q2 | Jun 30, 2025 | ITUS Capital | - | - | AUROBINDO.NS, BAJAJ-AUTO.NS, CUB.NS, DRREDDY.NS, EICHERMOT.NS, GILLETTE.NS, HDFCAMC.NS, HDFCBANK.NS, HINDUSTANCOPPER.NS, HINDZINC.NS, ICICIBANK.NS, IGI.NS, INTERGLOBE.NS, ITC.NS, MARICO.NS, PBFINTECH.NS, PIRAMALP.NS, TITAN.NS, TVSMOTOR.NS, VEDL.NS | Banking, earnings, India, infrastructure, Pharmaceuticals, tariffs, Valuations | US tariff policies are creating global trade volatility and uncertainty. The manager discusses how tariffs protect domestic industries at the expense of consumers and global welfare, while potentially increasing inflation and devaluing currency. This uncertain environment requires global allocators to rethink their marginal dollar allocation. | View | |
| 2024 Q1 | Apr 26, 2024 | Moon Capital Management | 0.0% | 23.0% | AAPL, AMZN, BTI, GOOGL, ITC.NS, META, MSFT, NVDA, PM, TSLA | earnings, Fed policy, Market Timing, rates, Tobacco, value | British American Tobacco represents a value opportunity trading at only 6x earnings despite generating robust free cash flows exceeding 16% yield. The company is successfully transitioning from traditional combustibles to reduced-risk products, with New Categories business growing 30% annually and turning profitable in 2023. BTI plans to use proceeds from ITC stake sales for share buybacks and debt reduction. | BTI |
View |
| 2025 Q1 | Mar 31, 2025 | ITUS Capital | - | - | ABB.NS, AUROPHARMA.NS, BAJAJ-AUTO.NS, DRREDDY.NS, EICHERMOT.NS, GILLETTE.NS, HAVELLS.NS, HDFCAMC.NS, HDFCBANK.NS, HINDCOPPER.NS, ICICIBANK.NS, ICICIGI.NS, ITC.NS, MARICO.NS, PBFINTECH.NS, PIRAMALP.NS, TITAN.NS, TVSMOTOR.NS, ULTRACEMCO.NS, VEDL.NS | banks, consumer, Government Spending, India, large cap, Pharmaceuticals, tariffs, valuation | Portfolio is overweight banks with focus on market leaders like ICICI Bank and HDFC Bank. Manager expects bottoms-up outlook on lending growth and views banks as offering better risk-reward at current valuations. | View | |
| 2024 Q4 | Dec 31, 2024 | ITUS Capital | - | - | AMBUJACEM.NS, AUROPHARMA.NS, BAJAJ-AUTO.NS, DRREDDY.NS, EICHERMOT.NS, GAIL.NS, HAVELLS.NS, HDFCAMC.NS, HDFCBANK.NS, ICICIBANK.NS, IEX.NS, ITC.NS, KEI.NS, LT.NS, MARICO.NS, PBFINTECH.NS, PIRAMALP.NS, POWERGRID.NS, RELIANCE.NS, TVSMOTOR.NS | Capex, Copper, Domestic Flows, healthcare, India, infrastructure, technology, Two Wheelers | Healthcare continues to be the largest exposure across portfolios with strong growth outlook benefiting from low-cost manufacturing and lower price erosion in US pharma. The manager expects CY25 to be a strong growth sector for pharma which is reflected across portfolio positioning. | ICICIGI.NS |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| No pitches found. | |||||||||
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||